Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Patricia L. WinokurN Legakis

Abstract

To evaluate the prevalence of extended-spectrum beta-lactamase (ESBL)-producing strains among species of Enterobacteriaceae, a microdilution susceptibility test was performed with strains of Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Salmonella species that were isolated as part of the SENTRY project. The highest percentage of ESBL phenotype (defined as a minimum inhibitory concentration [MIC] > or =2 microg/mL for ceftazidime, ceftriaxone, or aztreonam) was detected among K. pneumoniae strains from Latin America (45%), followed by those from the Western Pacific region (25%), Europe (23%), the United States (8%), and Canada (5%). P. mirabilis and E. coli strains for which MICs of extended-spectrum cephalosporins or monobactams were elevated also were more prominent in Latin America. Testing with ceftazidime revealed more isolates with elevated MICs than did testing with ceftriaxone or aztreonam. ESBL strains showed high levels of co-resistance to aminoglycosides, tetracycline, trimethoprim-sulfamethoxazole, and ciprofloxacin. Imipenem remains highly effective against ESBL strains. Organisms expressing an ESBL are widely distributed worldwide, although prevalence rates are significantly higher in certain geo...Continue Reading

References

Jan 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, L Sutton
Sep 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, A A Medeiros
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K BushA A Medeiros
Jan 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A PhilipponP H Lagrange
Sep 1, 1993·Annals of Internal Medicine·K S MeyerJ J Rahal
Jul 1, 1995·The Journal of Antimicrobial Chemotherapy·D Sirot
Aug 1, 1996·Journal of Clinical Microbiology·M G CormicanR N Jones
Jul 1, 1997·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·D L MonnetR P Gaynes
Jan 9, 1998·Infectious Disease Clinics of North America·G A Jacoby
Mar 31, 1998·Lancet·L Martínez-MartínezG A Jacoby

❮ Previous
Next ❯

Citations

Jan 22, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G MendelsonR Raz
May 7, 2009·Indian Journal of Pediatrics·Murat AnilNeval Agus
Sep 23, 2010·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Babu UmaYelavarthi Lakshmi Sarayu
Mar 17, 2004·Diagnostic Microbiology and Infectious Disease·Tsai-Ling LauderdaleUNKNOWN TSAR Participating Hospitals
Mar 25, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·Pattarachai KiratisinThanit Nunthanasup
Nov 26, 2003·FEMS Microbiology Letters·Letícia A M CarneiroMara L P Queiroz
Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·M A PfallerUNKNOWN MYSTIC Program Study Group
May 15, 2002·International Journal of Antimicrobial Agents·Jan PatzerPhilip Turner
Jan 28, 2005·The New England Journal of Medicine·George A Jacoby, Luisa Silvia Munoz-Price
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A PfallerH S Sader
Jun 28, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R OdehJ P Quinn
Sep 14, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John M QualeAdedeyo Adedeji
Dec 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel J DiekemaBradley N Doebbeling
Apr 20, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dolores Alcantar-CurielCelia M Alpuche-Aranda
Jul 21, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philip J Turner
Apr 6, 2006·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Kyungwon LeeYunsop Chong
Feb 4, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Samia RéjibaAmel Kechrid
Feb 2, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Umaer Naseer, Arnfinn Sundsfjord
May 27, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Abdulkader F TawfikMohamed H M Al-Agamy
Oct 22, 2008·Antimicrobial Agents and Chemotherapy·Ling MaUNKNOWN Taiwan Surveillance of Antimicrobial Resistance Project
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Michael R MulveyUNKNOWN Canadian Hospital Epidemiology Committee, Canadian Nosocomial Infection Surveillance Program, Health Canada
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·H SahlyU Ullmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.